(2S)-neopentyl 2-(chloro(naphthalen-1-yloxy)phosphorylamino)-3-methylbutanoate | 1234489-27-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S)-neopentyl 2-(chloro(naphthalen-1-yloxy)phosphorylamino)-3-methylbutanoate
• 英文别名: 2,2-dimethylpropyl (2S)-2-[[chloro(naphthalen-1-yloxy)phosphoryl]amino]-3-methylbutanoate
• CAS: 1234489-27-0
• 化学式: C₂₀H₂₇ClNO₄P
• 分子量: 411.865
• InChiKey: OPAQVMHUVXMMSO-HSYKDVHTSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.1
• 重原子数：
  27
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  64.6
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2',3'-O,O-isopropylidene-2'-C-β-methylguanosine 、 (2S)-neopentyl 2-(chloro(naphthalen-1-yloxy)phosphorylamino)-3-methylbutanoate 在 叔丁基氯化镁 作用下， 以 四氢呋喃 为溶剂， 以52%的产率得到2,2-dimethylpropyl (2S)-2-[[[(3aR,4R,6R,6aR)-4-(2-amino-6-oxo-1H-purin-9-yl)-2,2,3a-trimethyl-6,6a-dihydro-4H-furo[3,4-d][1,3]dioxol-6-yl]methoxy-naphthalen-1-yloxyphosphoryl]amino]-3-methylbutanoate
  参考文献：
  名称：

  2'- C-甲基鸟苷的磷酸氨基甲酸酯肽是丙型肝炎病毒的高效抑制剂。它们的体外和体内特性研究

  摘要：

  丙型肝炎病毒感染构成了严重的健康问题，需要更有效的治疗方法。具有改善的暴露，功效和选择性的核苷类似物被认为是未来HCV治疗的可能关键组成部分。2'- C-甲基鸟苷三磷酸已经被公认为是HCV RNA聚合酶的有效抑制剂，但是由于胞内磷酸化较差，亲本核苷仅具有中等活性。我们在此报告了氨基磷酸酯ProTide技术的应用，以绕过该核苷的限速初始磷酸化反应。据报道，有30多种新型ProTide，其中芳基，酯和氨基酸区域有所变化。升-丙氨酸化合物在复制子测定中被认为是有效的和选择性的HCV抑制剂，但尽管酯发生了很大的变化，但仍缺乏啮齿动物的血浆稳定性。保留苄基苄基酯部分的氨基酸变异增加了啮齿动物的稳定性，但以效力为代价。最后，具有酯变化的1-缬氨酸酯产生有效，稳定的化合物。对这些药剂在小鼠中的药代动力学研究表明，单次口服给药后，肝脏会暴露于具有生物活性的三磷酸酯类物质。ProTide和亲本核苷的全身暴露

  DOI：

  10.1021/jm1003792

文献信息

• Phosphoramidate Derivatives of Guanosine Nucleoside Compunds for Treatment of Viral Infections
  申请人：Chamberlain Stanley

  公开号：US20120052046A1

  公开（公告）日：2012-03-01

  Phosphoramidate compounds derived from guanine bases having enhanced therapeutic potency are provided, and these compounds in particular have enhanced potency with respect to treatment of viral infections, such as hepatitis C virus. Pharmaceutical compositions, methods of preparing the compounds, and methods of using the compounds and compositions to treat viral infections are also provided.

  本发明提供了从鸟嘌呤碱基衍生的磷酰胺化合物，具有增强的治疗效力，特别是对于治疗病毒感染，如丙型肝炎病毒，具有增强的效力。本发明还提供了制备该化合物的制药组合物、制备该化合物的方法以及使用该化合物和组合物治疗病毒感染的方法。
• Dual pro-drugs of 2′-C-methyl guanosine monophosphate as potent and selective inhibitors of hepatitis C virus
  作者：Christopher McGuigan、Karolina Madela、Mohamed Aljarah、Arnaud Gilles、Srinivas K. Battina、Changalvala V.S. Ramamurty、C. Srinivas Rao、John Vernachio、Jeff Hutchins、Andrea Hall、Alexander Kolykhalov、Geoffrey Henson、Stanley Chamberlain

  DOI：10.1016/j.bmcl.2011.06.013

  日期：2011.10

  We have previously reported the power of combining a 5'-phosphoramidate ProTide, phosphate prodrug, motif with a 6-methoxy purine pro-drug entity to generate highly potent anti-HCV agents, leading to agents in clinical trial. We herein extend this work with the disclosure that a variety of alternative 6-substituents are tolerated. Several compounds exceed the potency of the prior 6-methoxy leads, and in almost every case the ProTide is several orders of magnitude more potent than the parent nucleoside. We also demonstrate that these agents act as pro-drugs of 2'-C-methyl guanosine monophosphate. We have also reported the novel use of hepatocyte cell lysate as an ex vivo model for ProTide metabolism. (C) 2011 Elsevier Ltd. All rights reserved.
• US8759318B2
  申请人：——

  公开号：US8759318B2

  公开（公告）日：2014-06-24
• [EN] PHOSPHORAMIDATE DERIVATIVES OF GUANOSINE NUCLEOSIDE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS<br/>[FR] DÉRIVÉS DE PHOSPHORAMIDATE DE COMPOSÉS GUANOSINE NUCLÉOSIDE POUR LE TRAITEMENT D'INFECTIONS VIRALES
  申请人：UNIV CARDIFF

  公开号：WO2010081082A2

  公开（公告）日：2010-07-15

  Phosphoramidate compounds derived from guanine bases having enhanced therapeutic potency are provided, and these compounds in particular have enhanced potency with respect to treatment of viral infections, such as hepatitis C virus. Pharmaceutical compositions, methods of preparing the compounds, and methods of using the compounds and compositions to treat viral infections are also provided.